Amyloid‐related imaging abnormalities from trials of solanezumab for Alzheimer's disease
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Introduction: Solanezumab, a humanized monoclonal antibody that binds soluble amyloid beta peptide, is being developed for treatment of Alzheimer's disease (AD). Methods: Patients (n = 2042) with mild and moderate AD were randomized 1:1 to 400‐mg solanezumab or placebo infusion every 4 weeks for 80 weeks and 1457 patients entered an open‐label extension. Magnetic resonance imaging scans monitored for amyloid‐related imaging abnormalities‐edema/effusion (ARIA‐E) and amyloid‐related imaging abnormalities‐hemorrhage/hemosiderin deposition. Results: Sixteen patients (solanezumab, n = 11; placebo, n = 5) developed ARIA‐E during the double‐blind phase, and 7 patients developed ARIA‐E during the open‐label extension as of July 31, 2014. Unique cases are discussed including solanezumab patients who were given solanezumab, while ARIA‐E was present and a patient who developed ARIA‐E during placebo treatment and again during solanezumab treatment. Discussion: Asymptomatic ARIA‐E was detected in solanezumab‐treated and placebo‐treated AD patients. ARIA‐E occurs infrequently during solanezumab and placebo treatments but may occur repeatedly in some patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 4×
“Similar to the phase 2 studies, most ARIA-E cases in the phase 3 studies occurred within the first 3 doses (w39 weeks or 273 days) [6].”
BackgroundResultInfluentialPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Self-citationSubacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · cited 1×
“It is thought that more ARIA is associated with treatment with antiamyloid antibodies such as bapineuzumab and gantenerumab that target the N-terminal region of Ab because those epitopes are exposed in amyloid plaques [9] and are available for antibody binding.”
BackgroundSperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857 · cited 9×
“The percentages of patients with ARIA-E and ARIA-H were compared between treatment groups in EXPEDITION and EXPEDITION 2 using a Cochran-Mantel Haenszel test for general association controlling for study.”
BackgroundResultInfluentialSelf-citationA phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Self-citationSperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70015-7 · Cited by 512 · cited 12×
“The percentages of patients with ARIA-E and ARIA-H were compared between treatment groups in EXPEDITION and EXPEDITION 2 using a Cochran-Mantel Haenszel test for general association controlling for study.”
BackgroundMethodResultInfluentialSelf-citationMechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431 · cited 9×
“The percentages of patients with ARIA-E and ARIA-H were compared between treatment groups in EXPEDITION and EXPEDITION 2 using a Cochran-Mantel Haenszel test for general association controlling for study.”
BackgroundMethodInfluentialChalmers, K., Wilcock, G. K., & Love, S. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2003.00457.x · Cited by 156
Immunotherapy Reduces Vascular Amyloid- in PDAPP Mice
Schroeter, S., Khan, K., Barbour, R., Doan, M., Chen, M., Guido, T., Gill, D., Basi, G., Schenk, D., Seubert, P., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.2377-07.2008 · Cited by 133 · cited 1×
“Preclinical animal models suggest that repair and remodeling of cerebral vasculature occurs [15] after ARIA [16] that may prevent further occurrence [17].”
BackgroundZago, W., Schroeter, S., Guido, T., Khan, K., Seubert, P., Yednock, T., Schenk, D., Gregg, K. M., Games, D., Bard, F., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.010 · Cited by 75
Cited by
Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways
Greenberg, S. M., Bacskai, B. J., Hernandez-Guillamon, M., Pruzin, J., Sperling, R., & van Veluw, S. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0281-2 · Cited by 947
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., Démonet, J.-F., Garibotto, V., Giannakopoulos, P., Gietl, A., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30159-x · Cited by 626
Salloway, S., Chalkias, S., Barkhof, F., Burkett, P., Barakos, J., Purcell, D., Suhy, J., Forrestal, F., Tian, Y., Umans, K., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4161 · Cited by 619
Self-citationAlzheimer’s disease hypothesis and related therapies
Du, X., Wang, X., & Geng, M. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0107-y · Cited by 607
Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics
Hampel, H., Elhage, A., Cho, M., Apostolova, L. G., Nicoll, J. A. R., & Atri, A. (2023) · Brain · doi:10.1093/brain/awad188 · Cited by 412
“8,16,21,22 The GRE/T 2 * MRI sequence has a superior sensitivity to FLAIR and turbo spin-echo T 2 .”
BackgroundInfluential
Metadata
- Authors
- Carlson, C., Siemers, E., Hake, A., Case, M., Hayduk, R., Suhy, J., Oh, J., & Barakos, J.
- Venue
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Publisher
- Wiley
- Published
- 2016-01
- Volume
- 2
- Issue
- 1
- Pages
- 75-85
- ISSN
- 2352-8729 (ISSN-L)
- OpenAlex
- W2291453643
- Cited by
- 65
- References
- 10
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amyloid‐related imaging abnormalities from trials of solanezumab for Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.dadm.2016.02.004
- The paper
- Carlson, C., Siemers, E., Hake, A., Case, M., Hayduk, R., Suhy, J., Oh, J., & Barakos, J. (2016). Amyloid‐related imaging abnormalities from trials of solanezumab for Alzheimer's disease. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. https://doi.org/10.1016/j.dadm.2016.02.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.